stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) Revenue
Harmony Biosciences Holdings, Inc.'s revenue for fiscal 2025 was $868.5M, up 21.5% from $714.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was $989.4M. Over the past ten years it has ranged from $6.0M (fiscal 2019) to $868.5M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 6 consecutive fiscal years. Harmony Biosciences Holdings, Inc. ranks 26th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $868.5M | 21.51% |
| FY2024 | $714.7M | 22.80% |
| FY2023 | $582.0M | 32.93% |
| FY2022 | $437.9M | 43.35% |
| FY2021 | $305.4M | 91.21% |
| FY2020 | $159.7M | 2,564.59% |
| FY2019 | $6.0M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $268.9M | 2.92% |
| Jun 2026 | $261.3M | 21.31% |
| Mar 2026 | $215.4M | (11.65%) |
| Dec 2025 | $243.8M | 1.80% |
| 23 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| FTRE Fortrea Holdings Inc. compare | $2.7B |
| SRPT Sarepta Therapeutics, Inc. compare | $2.0B |
| HRMY Harmony Biosciences Holdings, Inc. | $989.4M |
| VIR Vir Biotechnology, Inc. compare | $302.8M |
| MESO Mesoblast Limited compare | $7.5M |
| TRVI Trevi Therapeutics, Inc. compare | — |
| MAZE Maze Therapeutics, Inc. compare | — |
| TRAX First Tracks Biotherapeutics, Inc. compare | — |
| REPL Replimune Group, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item